Significant Cure Rate Achieved in Babesiosis Study for SXTP
Three patients in an expanded access study were cured of babesiosis after receiving tafenoquine, indicating a potential 100% cure rate in immunosuppressed patients. This breakthrough could prompt a re-evaluation of treatment guidelines, presenting a substantial market opportunity for 60 Degrees Pharmaceuticals (SXTP) as no FDA-approved treatment currently exists.
View signal analysis